What genetic mutations are commonly found in Glioblastoma

Common Genetic Mutations in Glioblastoma

Glioblastoma, the most aggressive type of brain tumor, typically develops through accumulation of multiple genetic mutations. Here are the most commonly identified ones:

Most Frequent Mutations

TP53 Mutations (found in ~60-80% of cases)

• The TP53 gene normally acts as a "tumor suppressor" — essentially a cellular brake that prevents uncontrolled growth
• When mutated, cells lose this protective mechanism and can divide uncontrollably
• This is one of the earliest changes in glioblastoma development

PTEN Loss (found in ~40% of cases)

• PTEN is another tumor suppressor gene that regulates cell growth signals
• Loss of PTEN removes a key growth-limiting mechanism, allowing cancer cells to proliferate more aggressively

EGFR Amplification/Mutation (found in ~40-50% of cases)

• EGFR (Epidermal Growth Factor Receptor) is a growth signal receptor on cell surfaces
• When amplified or mutated, it sends constant "grow" signals to the cell, even without external stimulation
• This is particularly important because it can be targeted with certain therapies

IDH1/IDH2 Mutations (found in ~5-10% of primary glioblastomas)

• These mutations are more common in secondary glioblastomas (tumors that progressed from lower-grade brain tumors)
• IDH mutations affect cellular metabolism and are associated with somewhat better prognosis
• Tumors with IDH mutations are classified differently and may respond differently to treatment

Other Important Mutations

ATRX Loss (found in ~50% of cases)

• Affects DNA repair and chromosome stability
• Often co-occurs with TP53 mutations

RB Pathway Alterations (found in ~70% of cases)

• The RB gene normally controls cell cycle progression
• Loss allows cells to bypass normal growth checkpoints

NF1 Loss (found in ~20% of cases)

• NF1 is a tumor suppressor involved in growth signal regulation

Why This Matters for Treatment

Understanding these mutations is clinically important because:

• Some mutations can be targeted with specific drugs (like EGFR inhibitors)
• Mutation patterns help predict how aggressive the tumor may be
• They inform decisions about which combination of treatments might be most effective
• Genetic testing can guide personalized treatment approaches

Important Note About Molecular Testing

Your oncology team may recommend molecular profiling of your tumor tissue to identify which specific mutations are present in YOUR glioblastoma. This information can be valuable for:

• Determining which targeted therapies might be appropriate
• Identifying clinical trials that match your tumor's genetic profile
• Understanding prognosis and treatment response patterns

Questions to Ask Your Care Team

1. Has my tumor been tested for these genetic mutations? If so, which ones were found?
2. Do any of my tumor's mutations suggest specific targeted therapy options?
3. Are there clinical trials available that target the mutations found in my tumor?
4. How do my tumor's genetic characteristics affect the treatment recommendations you're making?
5. Should I consider additional molecular testing or second opinions based on my mutation profile?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.